India markets open in 5 hours 26 minutes
  • BSE SENSEX

    52,699.00
    +392.92 (+0.75%)
     
  • Nifty 50

    15,790.45
    +103.50 (+0.66%)
     
  • Dow

    34,196.82
    +322.58 (+0.95%)
     
  • Nasdaq

    14,369.71
    +97.98 (+0.69%)
     
  • BTC-INR

    2,565,151.75
    +90,519.25 (+3.66%)
     
  • CMC Crypto 200

    837.58
    +50.96 (+6.48%)
     
  • Hang Seng

    28,882.46
    +65.39 (+0.23%)
     
  • Nikkei

    28,875.23
    +0.34 (+0.00%)
     
  • EUR/INR

    88.4816
    +0.0185 (+0.02%)
     
  • GBP/INR

    103.2192
    -0.2911 (-0.28%)
     
  • AED/INR

    20.1420
    +0.0010 (+0.00%)
     
  • INR/JPY

    1.4924
    -0.0014 (-0.09%)
     
  • SGD/INR

    55.2170
    +0.1210 (+0.22%)
     

NeuBase Therapeutics to Participate in Upcoming Investor Conferences in May 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.

RBC Capital Markets Virtual Global Healthcare Conference Fireside Chat at 11:30 a.m. ET on May 19

Oppenheimer Rare & Orphan Disease Summit presentation on May 21

PITTSBURGH, May 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a virtual fireside chat at the RBC Capital Markets Virtual Global Healthcare Conference, as well as present a corporate overview and business update at the Oppenheimer Rare & Orphan Disease Summit, which are both being held in May 2021.

Conferences Details:

Event:

RBC Capital Markets Virtual Global Healthcare Conference

Format:

Fireside Chat

Date:

Wednesday, May 19th

Time:

11:30 a.m. ET

Location:

Webcast Link – or at the company’s website (click here)

Event:

Oppenheimer Rare & Orphan Disease Summit

Format:

Presentation

Date:

Friday, May 21st

Location:

Webcast Link – or at the company’s website (click here)

About NeuBase Therapeutics
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.

NeuBase Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
OP: (617) 430-7576

NeuBase Media Information:

Jessica Yingling, Ph.D.
Little Dog Communications Inc.
(858) 344-8091
jessica@litldog.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting